LP3 Network Free Webinar - Veterinary Compounding, A Customized Approach

Download in electronic PDF format for $25



Search the Complete Journal Archives

Pharmacogenomics: The End of Trial-and-Error Medicine?

Author(s):  Vail Jane

Issue:  Jan/Feb 2007 - Pediatric Patients
View All Articles in Issue

Abstract:  “The right dose of the right drug for the right indication for the right patient at the right time.” In those words, Dr. Felix Frueh captured the essence of pharmacogenomics and the goal of all compounding pharmacists. Pharmacogenomics provides the tools for prescribing personalized drug therapy that will improve treatment outcomes, decrease the incidence of drug-related adverse effects, and ultimately reduce the cost of medical care. The use of pharmacogenomics in clinical practice is changing as new discoveries make it possible and cost-effective to identify a patient’s unique genetic makeup and apply this information to treating medical ailments. With a prescription and the patient’s pharmacogenomic profile in mind, a compounding pharmacist can prepare a customized medication that delivers that patient’s unique best dosage in the optimal dosage form.

Related Keywords: PERSONALIZED MEDICINE, INDIVIDUALIZED MEDICINE, PHARMACOGENOMICS, GENOMICS, GENOME, GENETIC TESTING, RESEARCH, FDA, US FOOD AND DRUG ADMINISTRATION, TRIAL, CUSTOMIZED, JANET WOODCOCK

Related Categories: LEGAL, TECHNOLOGY, PROFESSIONAL ISSUES, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Pharmacogenomics: The End of Trial-and-Error Medicine? Vail Jane Jan/Feb 2007 59-65 Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2 Allen Loyd V Jul/Aug 2015 280-287 Buy
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G Jul/Aug 2015 303-305 Buy
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr Nov/Dec 2015 487-488 Buy
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse Jul/Aug 2007 326-327 Buy
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G May/Jun 2014 208 Buy
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Allen Loyd V Jr, Ashworth Lisa D Jan/Feb 2005 44-46 Buy
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr Sep/Oct 2015 389-390 Buy
Quality Control: Microbial Limit Tests for Nonsterile Pharmaceuticals, Part 2 Vu Nicole, Lou Jessica R, Kupiec Thomas C Jul/Aug 2014 305-310 Buy